Ocular Immunology and Inflammation最新文献

{"title":"Structural Retinal and Choroidal Changes in Toxoplasmic Retinochoroiditis Assessed by Swept-Source Optical Coherence Tomography.","authors":"Ramavath Sree Keerti, Manjit Boro, Muhsin Hashim, Alejandra De-La-Torre, Jyotirmay Biswas","doi":"10.1080/09273948.2026.2654782","DOIUrl":"https://doi.org/10.1080/09273948.2026.2654782","url":null,"abstract":"<p><strong>Purpose: </strong>To demonstrate retinal and choroidal structural changes across distinct disease activity phases in toxoplasma retinochoroiditis (TRC) using swept-source optical coherence tomography (SS-OCT) and establishing stage-specific imaging biomarkers for therapeutic decisions and monitoring.</p><p><strong>Methods: </strong>Retrospective analytical study of 33 patients (39 eyes) with TRC (2017-2024) at a tertiary uveitis clinic. Eyes categorized as active (<i>n</i> = 5), reactive (<i>n</i> = 13), or inactive (<i>n</i> = 27) using standardized clinical/serological criteria. SS-OCT measured central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), retinal layers, and vitreous changes. Interobserver reproducibility assessed via intraclass correlation coefficients (ICC). Continuous parameters compared using Kruskal-Wallis H test with Dunn's post-hoc correction. Multivariate logistic regression controlled for age, sex, lesion location, and bilaterality.</p><p><strong>Results: </strong>Mean age 25.4 ± 16.6 years (21 M:12F), 6 bilateral cases. BCVA improved from 0.67 ± 0.58 to 0.47 ± 0.42 logMAR (<i>p</i> < 0.05). Active eyes showed highest CFT (median 192 μm, range 95-420 μm), SFCT (median 412 μm), posterior hyaloid thickening (100%), vitreous hyperreflective dots (80%), and intraretinal/subretinal fluid (60%). Reactive eyes had intermediate thickness, RPE hyperreflectivity (84.6%), and outer retinal atrophy (92.3%). Inactive eyes demonstrated thinning, ellipsoid zone disruption (100%), RPE loss (100%), and epiretinal membranes (81.5%). Kruskal-Wallis: CFT H = 12.4, <i>p</i> = 0.002; SFCT H = 9.8, <i>p</i> = 0.007. Serous retinal detachment 17.9% (mostly active), no recurrence. ICC > 0.85 confirmed measurement reproducibility.</p><p><strong>Conclusions: </strong>SS-OCT reveals distinct structural signatures across TRC phases: active disease shows retinal edema and vitreoretinal disruption; reactive phases exhibit transitional remodeling; inactive disease manifests chronic atrophy. SS-OCT validates quantifiable disease staging, treatment monitoring, and prognostication. Future multimodal imaging studies needed.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-10"},"PeriodicalIF":2.0,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Life Evaluation of the Revised IWOS, Modified Abad and SUN Criteria in a Multicenter Cohort of 409 Patients with Sarcoid Uveitis.","authors":"Margot Cargnelutti, Robin Jacquot, Thomas El-Jammal, Amy Siriphanh, Laurent Kodjikian, Stéphane Abramowicz, Pascal Sève","doi":"10.1080/09273948.2026.2667779","DOIUrl":"https://doi.org/10.1080/09273948.2026.2667779","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate and compare the International Workshop on Ocular Sarcoidosis (IWOS) revised diagnostic criteria, the modified Abad diagnostic criteria, and the Standardization of Uveitis Nomenclature (SUN) classification criteria in patients with sarcoid uveitis in a real-life setting.</p><p><strong>Methods: </strong>This multicenter cohort study included 409 patients with sarcoid uveitis managed at the Hospices Civils de Lyon between 2003 and 2024. All patients fulfilled the revised IWOS, modified Abad, and/or SUN criteria. Systemic and ophthalmologic data were retrospectively collected, and diagnostic confidence levels (definite, presumed, or probable sarcoid uveitis) were assigned for each scoring system.</p><p><strong>Results: </strong>Uveitis was often bilateral (79.1%) and granulomatous (73.7%). Panuveitis accounted for 43.3% of cases and anterior uveitis for 23.7% of cases. Bilateral hilar lymphadenopathy (BHL) was frequently observed on chest computed tomography (63.7%), along with elevated serum ACE levels (59.3%), and 18F-FDG PET was suggestive of sarcoidosis in 89.7% of 261 patients. Sarcoid uveitis was histologically confirmed in 71.5% of patients. The modified Abad criteria had the highest sensitivity (99.3%), followed by the IWOS (90.1%), and SUN criteria (83.4%). Exclusion from IWOS criteria was due to insufficient ophthalmologic signs (65.0%) or BHL absence (70.0%). Exclusion from SUN criteria was due to BHL absence (91.0%) or positive tuberculosis screening (29.8%).</p><p><strong>Conclusions: </strong>The modified Abad criteria were the most sensitive for diagnosing sarcoid uveitis. The IWOS criteria sensitivity was lower due to stricter ophthalmologic and radiologic requirements. The SUN criteria sensitivity was lower due to stricter radiologic criteria and exclusion of patients with a positive tuberculosis screening.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-9"},"PeriodicalIF":2.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Outer Retinal Necrosis Following Mumps Infection: A Case Series and Literature Review.","authors":"Radhika Thundikandy, Rathinam S R, Aswin P R, Anjana Somanath","doi":"10.1080/09273948.2025.2584917","DOIUrl":"https://doi.org/10.1080/09273948.2025.2584917","url":null,"abstract":"<p><strong>Purpose: </strong>To describe a case series of three patients, one adult and two children with bilateral cerebriform retinitis following clinically diagnosed mumps parotitis.</p><p><strong>Methods: </strong>Case reports of three cases of post mumps retinitis with literature review.</p><p><strong>Results: </strong>All three patients showed cerebriform retinitis throughout the fundus with OCT showing predominantly outer retinal necrosis. All three patients received systemic steroids.  Case 3 in addition received hyperbaric oxygen therapy (HBO).</p><p><strong>Conclusion: </strong>Cerebriform retinitis is a devastating complication of mumps parotitis. Response to systemic steroids was not very satisfactory. HBO therapy however showed encouraging results. Early management can hasten visual recovery.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-9"},"PeriodicalIF":2.0,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuro-Behçet's Syndrome Developing During Follow-Up for Behçet Uveitis: A Tertiary Uveitis Center Experience.","authors":"Nilufer Zorlutuna Kaymak, Ezgi Tanyeri Kılınç, Ilknur Sunğu, Murat Oklar, Ahmet Kasim Kılıç, Mehmet Engin Tezcan","doi":"10.1080/09273948.2026.2667772","DOIUrl":"https://doi.org/10.1080/09273948.2026.2667772","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the clinical, neurological, and neuropsychiatric characteristics, subtype distribution, and multidisciplinary management in patients developing Neuro-Behçet's syndrome (NBS) during follow-up for Behçet uveitis (BU).</p><p><strong>Methods: </strong>This retrospective study included 12 patients with panuveitis who developed NBS during follow-up for uveitis. Demographic data, ophthalmic findings, neurological and neuropsychiatric manifestations, neuroimaging results, cerebrospinal fluid (CSF) analyses, and treatments were reviewed. Neurological involvement was classified into parenchymal, vascular, neuropsychiatric, and peripheral types.</p><p><strong>Results: </strong>Among 300 consecutive patients with BU followed in our tertiary uveitis clinic, 12 patients (4%) developed NBS during follow-up. Parenchymal involvement was the most frequent subtype (50%), primarily affecting the brainstem, while neuropsychiatric symptoms occurred in 41.7% of patients. Headache and behavioral changes often preceded neurological deficits, and some patients showed subclinical imaging findings. Neuropsychiatric cases demonstrated higher pathergy positivity and skin lesions, whereas genital ulcers were more common in parenchymal and mixed involvement. Notably, 41.7% of patients had active uveitis at the time of NBS onset, suggesting that neurological involvement can occur independently of ocular inflammatory activity. Management required escalation of systemic therapy, including pulse steroids and biologics. At final follow-up, visual acuity remained stable (<i>p</i> > 0.05) with no permanent neurological sequelae.</p><p><strong>Conclusion: </strong>In this uveitis cohort, NBS developed in 4% of patients with BU. Because neurological involvement may occur subclinically or independently of ocular activity, clinicians should maintain a high index of suspicion for neurological and neuropsychiatric manifestations. A prompt multidisciplinary approach and timely treatment escalation are essential to prevent permanent neurological damage in this patient population.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-8"},"PeriodicalIF":2.0,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proportion, Incidence, and Pattern of New-Onset Uveitis in Patients Aged 60 and Above: A Systematic Review.","authors":"Ninglu Weng, Amir Vosoughi, Parsa Mehraban Far, Sterling King, Imane Marrakchi, Andre Jastrzebski","doi":"10.1080/09273948.2025.2608932","DOIUrl":"https://doi.org/10.1080/09273948.2025.2608932","url":null,"abstract":"<p><strong>Purpose: </strong>Uveitis is commonly regarded as a disease of young and middle-aged adults, with new-onset cases in older individuals frequently attributed to masquerade syndromes, particularly of neoplastic origin. However, few studies have examined the epidemiology or clinical patterns of new-onset uveitis in adults aged 60 years and older. We conducted the first systematic review to evaluate the proportion, incidence, and clinical features of uveitis in this demographic.</p><p><strong>Methods: </strong>A systematic search of MEDLINE and Embase was conducted in September 2024. Studies published from January 2005 to September 2024 were included if they reported on the proportion or etiology of incident uveitis in patients aged 60 and above. Screening was conducted independently in duplicate. Descriptive statistics (median percentages [interquartile range (IQR)]) were used to summarize findings.</p><p><strong>Results: </strong>Forty studies met inclusion criteria, encompassing 262 716 patients. The proportion of patients aged 60 and older was 23.0% (IQR:14.6%). Developed countries reported higher proportions than developing countries (26.6% [IQR: 17.6%] versus 14.1% [IQR: 10.3%], <i>p</i> = 0.006). The mean incidence among six studies was 159.8 per 100 000 person-years. Anterior uveitis was the most common anatomical subtype (59.8% [IQR: 23.2%]). Leading etiologies included idiopathic, herpetic, sarcoidosis, tuberculosis, and HLA-B27-associated uveitis, with infectious etiologies reported more frequently in developing regions. Masquerade syndromes accounted for 4.9% (IQR: 4.1%) of cases, 94.9% of which were neoplastic, most commonly lymphoma. Risk of bias tools were not uniformly applicable, limiting quality assessment.</p><p><strong>Conclusions: </strong>These findings suggest that uveitis is both prevalent and distinct in presentation, warranting age-specific diagnostic consideration.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-8"},"PeriodicalIF":2.0,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147818168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Familial Granulomatous Uveitis with Arthritis Suggestive of Blau Syndrome: A Multigenerational Case Series from India.","authors":"Parul Jain, Vanditaa Agrrawal, Sumeet Singla, Nita Khurana, Sunidhi Rauthan","doi":"10.1080/09273948.2026.2651789","DOIUrl":"10.1080/09273948.2026.2651789","url":null,"abstract":"<p><strong>Purpose: </strong>Blau syndrome is a rare autosomal dominant autoinflammatory disorder characterized by granulomatous dermatitis, arthritis, and uveitis resulting from gain-of-function mutations in the NOD2 gene. In India, the condition is frequently underrecognized or misdiagnosed due to significant clinical overlap with juvenile idiopathic arthritis associated uveitis and early onset sarcoidosis. Reports of familial Blau syndrome are rare. This report describes familial granulomatous uveitis suggestive of Blau syndrome, with emphasis on ocular manifestations, diagnostic challenges and treatment outcomes in the absence of genetic testing.</p><p><strong>Methods: </strong>A mother and her two children presenting with variable combinations of arthritis, cutaneous lesions and ocular inflammation were evaluated. Detailed ophthalmic examination, systemic assessment, laboratory investigations, tuberculosis screening, and histopathologic analysis were performed. Diagnostic reasoning was based on clinicopathologic correlation and familial clustering.</p><p><strong>Results: </strong>Granulomatous uveitis was identified in the mother and the elder child, with the mother exhibiting advanced disease likely due to delayed diagnosis and treatment. Skin biopsy in the elder child demonstrated well-formed non-caseating epithelioid granulomas with negative acid-fast bacilli staining. All three patients were treated with methotrexate, with adjunct corticosteroids as required. Ocular inflammation remained quiescent on follow-up, with stabilization of visual function in the affected eyes.</p><p><strong>Conclusion: </strong>This family illustrates the classic yet variably expressed ocular phenotype suggestive of Blau syndrome. The report highlights the role of ophthalmologists in early recognition of the disease, particularly in tuberculosis-endemic regions. Early diagnosis and prompt immunomodulatory therapy are essential to prevent irreversible visual morbidity, especially when genetic testing is not readily available.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"875-878"},"PeriodicalIF":2.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Posterior Vitrectomy in Uveitis: Experience from a Tertiary Referral Center in Colombia.","authors":"Carlos Mario Rangel, Germán Mejía-Salgado, Laura M Duarte-Bueno, Laura Torres Parada, María Alejandra Gómez Rocha, Marcos Restrepo Arango","doi":"10.1080/09273948.2026.2653798","DOIUrl":"10.1080/09273948.2026.2653798","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the outcomes of pars plana vitrectomy (PPV) in patients with uveitis, including changes in visual acuity, inflammatory control, and macular edema status, in a sample from Colombia.</p><p><strong>Methods: </strong>A retrospective observational study was conducted on 27 eyes from 27 patients with uveitis who underwent PPV at a tertiary referral center. PPV was not performed as primary treatment for active uveitis; instead, it was undertaken only when postponement posed a risk of irreversible visual loss due to structural complications or when diagnostic clarification was urgently required. Aqueous/vitreous sampling was performed with PPV when indicated for etiologic evaluation. Collected data included demographics, uveitis classification, surgical indication, best-corrected visual acuity (BCVA) at 1, 3, 6, and 12 months in LogMAR, inflammatory activity (defined with vitreous haze and anterior chamber cellularity) one month postoperatively, and cystoid macular edema (CME) status six months after PPV.</p><p><strong>Results: </strong>PPV was therapeutic in 20 eyes (74.1%), whereas in 7 cases (25.9%), it was performed with vitreous sampling. Mean baseline BCVA was 1.37 ± 1.06 and improved to 0.63 ± 0.70 at final follow-up. A gain of ≥0.3 was achieved in 14 eyes (51.9%) at one month and 17 eyes (63.0%) at 6 months. At one month, 26 eyes (96.2%) had a clear vitreous cavity. CME was present in only 3 eyes (11%) at six months postoperatively.</p><p><strong>Conclusion: </strong>In this sample, PPV demonstrated its utility for clarifying uncertain uveitis etiology, no deterioration, and, in some cases, improvement of visual acuity, and enabling adequate visualization for the evaluation and monitoring of CME.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"834-844"},"PeriodicalIF":2.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Non-Infectious Uveitis Associated with Medications for Substance Use Disorders.","authors":"Matthew J Schulgit, Ashley Hailer, Margaret G Miller, David C Kaelber, Natasha Kesav, Akhil Anand","doi":"10.1080/09273948.2026.2639733","DOIUrl":"10.1080/09273948.2026.2639733","url":null,"abstract":"<p><strong>Purpose: </strong>The association between drugs used for medication-assisted treatment (MAT) and the risk of noninfectious uveitis (NIU) remains unclear. To this end, we aimed to evaluate the risk of NIU in patients prescribed MAT compared with those prescribed selective serotonin reuptake inhibitors (SSRIs).</p><p><strong>Methods: </strong>This retrospective, population-based cohort study utilized aggregated, deidentified electronic health record data from the TriNetX Research Network. Analyses were conducted with and without exclusions for specific inflammatory risk factors. The control cohort comprised patients prescribed SSRIs, matched for age, sex, race, ethnicity, and smoking status. We compared the prescription of MAT to SSRIs to ascertain NIU risk against a risk-neutral medication. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated to assess the association between MAT and NIU risk. Analyses included specific NIU subtypes: anterior, intermediate, posterior, and pan-uveitis.</p><p><strong>Results: </strong>In the low inflammatory risk analysis, MAT prescriptions were not associated with increased risk of NIU through 6 months post prescription compared with SSRIs. In the real-world analysis, MAT prescriptions were associated with an increased risk of posterior NIU at 1 month (RR, 1.44; 95 % CI: 1.11-1.85), 3 months (RR, 1.44; 95 % CI: 1.14-1.83), and 6 months (RR, 1.44; 95 % CI: 1.16-1.80).</p><p><strong>Conclusions: </strong>MAT prescriptions may be associated with a mild increased risk of posterior NIU in the real-world setting, but not the low inflammatory risk setting, compared with SSRIs. These findings suggest a potential benefit of ophthalmologic monitoring in patients prescribed MAT, although institutional studies reviewing each medication are necessary to confirm these results.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"747-753"},"PeriodicalIF":2.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Neoplastic Uveitis Masquerade Syndromes: Insights from a Case Series.","authors":"Abhilasha Baharani","doi":"10.1080/09273948.2026.2652501","DOIUrl":"10.1080/09273948.2026.2652501","url":null,"abstract":"<p><strong>Purpose: </strong>To study the clinical characteristics and implications of non-neoplastic uveitis masquerade syndromes (NNUMS).</p><p><strong>Methods: </strong>A retrospective study of 1595 patients referred for evaluation of uveitis at a tertiary referral center in South India between July 2019 and July 2025. The clinical characteristics and outcomes of patients with NNUMS were evaluated.</p><p><strong>Results: </strong>Eighty eyes of 53 patients (40 males [75.5%], 13 females [24.5%] mean age 40.3 ± 15.7 years) were diagnosed with NNUMS. Forty-four (83%) patients had fundus lesions. Multimodal imaging was crucial in establishing the diagnosis in 46 (86.8%) patients. Retinal vascular diseases (22.6%), inherited retinal diseases (20.8%) and central serous chorioretinopathy (11.3%) were the most common etiological diagnoses. In 13 (24.5%) patients the diagnosis was delayed by more than 100 days. Twenty-seven (50.9%) patients were receiving anti-inflammatory therapy at presentation. The likelihood of unnecessary anti-inflammatory treatment was significantly higher (<i>p</i> < 0.001) in patients with a diagnostic delay >100 days than those without. Thirteen (24.5%) patients had underlying systemic disease, 92% of whom were previously undiagnosed until the ocular diagnosis was made. Retinal vascular involvement was significantly (<i>p</i> < 0.0001) associated with presence of underlying systemic condition.</p><p><strong>Conclusions: </strong>NNUMS are a heterogenous group of clinical entities which mimic ocular inflammatory diseases often resulting in misdiagnosis and unnecessary anti-inflammatory treatment. Recognizing the clinical and imaging features of common clinical manifestations is key to accurate diagnosis and reducing visual morbidity.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"813-825"},"PeriodicalIF":2.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147675512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypertensive Anterior Uveitis Following Intravitreal Faricimab.","authors":"Ellen Y Rhodes, Julia L Xia, Talisa E de Carlo Forest, Niranjan Manoharan, Alan G Palestine, Amit K Reddy","doi":"10.1080/09273948.2026.2658753","DOIUrl":"10.1080/09273948.2026.2658753","url":null,"abstract":"<p><strong>Purpose: </strong>Describe findings of three cases of culture and PCR negative hypertensive anterior uveitis following intravitreal faricimab.</p><p><strong>Methods: </strong>This is a case series of three patients undergoing treatment for diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD). Data collected included visual acuity, intraocular pressure (IOP), slit lamp examination (SLE), anterior chamber (AC) tap, vitreous tap with culture, and fluorescein angiography (FA).</p><p><strong>Results: </strong>Three patients developed hypertensive uveitis following repeated intravitreal faricimab injections for DME or nAMD. All presented within 2-5 weeks of injection with ocular pain and redness. Exam revealed elevated intraocular pressure (22-52 mmHg), and keratic precipitates with anterior chamber inflammation. Infectious and inflammatory workups, including aqueous and/or vitreous PCR for HSV, VZV, and CMV, were negative in all cases. Faricimab was discontinued and topical and/or local corticosteroids initiated, with adjunctive IOP-lowering therapy as indicated. Inflammation resolved in all patients within 3 months without recurrence after switching intravitreal anti-VEGF agents. Final visual acuity ranged from 20/25 to count fingers, limited by glaucomatous optic neuropathy in one case.</p><p><strong>Conclusions: </strong>Hypertensive anterior uveitis with diffuse KPs is a potential rare complication of intravitreal faricimab and must be considered in patients presenting with new ocular inflammation or IOP elevation while undergoing treatment with faricimab. The intraocular inflammation appears to respond well to discontinuation of faricimab and treatment with local corticosteroids.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"852-857"},"PeriodicalIF":2.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}